RecruitingPhase 3NCT05717803

Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

Segmentectomy for Ground Glass-dominant Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial


Sponsor

Fudan University

Enrollment

307 participants

Start Date

Feb 15, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: * The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm; * The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two surgical approaches for a specific type of early lung cancer — a ground glass-dominant invasive lung tumor 2-3 cm in size: a more limited removal called segmentectomy (removing only the affected segment of the lung) versus the standard lobectomy (removing an entire lobe). The aim is to see if the smaller surgery is just as effective while preserving more lung function. **You may be eligible if...** - You are between 18 and 80 years old - You have an early-stage lung adenocarcinoma that appears as a "ground glass" nodule 2-3 cm in size with a low solid component ratio (CTR 0-0.5) on CT scan - You have not had prior lung cancer surgery or received prior chemotherapy or radiation for this cancer - The tumor can be completely removed surgically **You may NOT be eligible if...** - Your tumor's solid-to-total size ratio or size falls outside the study parameters - You have received prior lung cancer surgery, chemotherapy, or radiation - The tumor cannot be fully removed - Your tumor is not confirmed as lung adenocarcinoma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESegmentectomy

The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.


Locations(1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05717803


Related Trials